The 6th Annual "Accelerating Research & Treatments for Castleman Disease" Working Dinner Meeting, an ancillary meeting to the American Society of Hematology Annual Meeting, took place on December 9th in Atlanta, GA. It was a wonderful opportunity for over 50 Castleman disease physicians and researchers to come together to discuss key CDCN priorities including a global patient registry, patient care, and international research agenda. The CDCN is looking forward to continuing the conversation and pushing forward in our efforts to defeat Castleman disease.
Abstracts from the four poster presentations can be found here:
- Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes
- Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease
- Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach
- Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses
Sponsorship: Janssen Pharmaceuticals has generously sponsored this year's Working Dinner meeting! We are grateful for their support of the CD community.
History: The CDCN held its first "Accelerating research & treatment for Castleman disease" meeting at the American Society of Hematology (ASH) 2012 meeting in Atlanta, GA. Thirty physicians, physician-scientists, and pharmaceutical partners from around the world joined us to share the latest discoveries around Castleman disease, which demonstrated clinician interest, determined initial priorities, and built tremendous momentum for the CDCN.
The CDCN held a second "Accelerating research & treatment for Castleman disease" meeting at ASH 2013 meeting in New Orleans, LA. A diverse group of over 50 hematologists, pathologists, physician-scientists, translational researchers, and pharmaceutical partners joined us for the meeting, which focused on the gaps that exist in the current state of knowledge and means for filling those gaps.
Over 50 physicians and researchers attended the CDCN's third annual "Accelerating research and treatment for Castleman disease" meeting during ASH 2014 meeting in San Francisco, CA. The fourth annual meeting during ASH 2015 in Orlando, FL was a huge success with over 50 physicians and researchers attending and key priorities coming from the meeting. The fifth annual meeting occurred at ASH 2016 in San Diego, CA.